Open questions on vorasidenib

Area of Science:

• Neuro-oncology
• Molecular oncology
• Clinical trials

Background:

• Isocitrate dehydrogenase (IDH)-mutant gliomas are a distinct subtype of brain tumors.
• Vorasidenib has shown efficacy in IDH-mutant grade 2 gliomas.
• Current understanding of vorasidenib's long-term effects and optimal use is evolving.

Purpose of the Study:

• To summarize open questions regarding vorasidenib's long-term benefit in IDH-mutant grade 2 gliomas.
• To discuss the optimal use of vorasidenib in IDH-mutant grade 2 gliomas.
• To explore the potential use of vorasidenib in IDH-mutant grade 3 and 4 gliomas.

Main Methods:

• Review of updated results from the INDIGO trial.
• Analysis of potential mechanisms of action, including differentiation therapy.
• Consideration of advanced imaging techniques for response assessment (volumetric analysis, amino acid PET).

Main Results:

• Vorasidenib may act as a differentiation therapy in IDH-mutant grade 2 gliomas.
• Updated INDIGO trial results suggest additional benefits in seizure control.
• Contrast-enhancement may be a better indicator for treatment response than histological grade, suggesting potential use in selected grade 3 gliomas.

Conclusions:

• Vorasidenib is emerging as a first-line treatment for many IDH-mutant grade 2 gliomas.
• Ongoing research aims to clarify its long-term impact on cognition, quality of life, and overall survival.
• Further trials are investigating vorasidenib's role in other contexts, including maintenance therapy and combination treatments.